DK3083627T3 - [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis - Google Patents

[1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis Download PDF

Info

Publication number
DK3083627T3
DK3083627T3 DK14825046.7T DK14825046T DK3083627T3 DK 3083627 T3 DK3083627 T3 DK 3083627T3 DK 14825046 T DK14825046 T DK 14825046T DK 3083627 T3 DK3083627 T3 DK 3083627T3
Authority
DK
Denmark
Prior art keywords
proteasomin
protozoic
leishmaniasis
triazol
inhibitors
Prior art date
Application number
DK14825046.7T
Other languages
Danish (da)
English (en)
Inventor
Agnes Biggart
Fang Liang
Casey Jacob Nelson Mathison
Valentina Molteni
Advait Suresh Nagle
Frantisek Supek
Vince Yeh
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52302387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3083627(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3083627T3 publication Critical patent/DK3083627T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK14825046.7T 2013-12-19 2014-12-18 [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis DK3083627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918089P 2013-12-19 2013-12-19
PCT/US2014/071077 WO2015095477A1 (en) 2013-12-19 2014-12-18 [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis

Publications (1)

Publication Number Publication Date
DK3083627T3 true DK3083627T3 (da) 2019-01-02

Family

ID=52302387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14825046.7T DK3083627T3 (da) 2013-12-19 2014-12-18 [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis

Country Status (41)

Country Link
US (6) US9303034B2 (enExample)
EP (1) EP3083627B1 (enExample)
JP (1) JP6392352B2 (enExample)
KR (1) KR102354082B1 (enExample)
CN (1) CN106029666B (enExample)
AP (1) AP2016009329A0 (enExample)
AR (1) AR098844A1 (enExample)
AU (1) AU2014364565B2 (enExample)
BR (1) BR112016014004B1 (enExample)
CA (1) CA2932870C (enExample)
CL (1) CL2016001421A1 (enExample)
CR (1) CR20160334A (enExample)
CU (1) CU24379B1 (enExample)
CY (1) CY1121060T1 (enExample)
DK (1) DK3083627T3 (enExample)
EA (1) EA030823B1 (enExample)
EC (1) ECSP16067921A (enExample)
ES (1) ES2701087T3 (enExample)
GT (1) GT201600131A (enExample)
HR (1) HRP20182021T1 (enExample)
HU (1) HUE040254T2 (enExample)
IL (1) IL246034B (enExample)
LT (1) LT3083627T (enExample)
MA (1) MA39186A1 (enExample)
MX (1) MX368072B (enExample)
MY (1) MY175865A (enExample)
NZ (1) NZ721650A (enExample)
PE (1) PE20160865A1 (enExample)
PH (1) PH12016501198A1 (enExample)
PL (1) PL3083627T3 (enExample)
PT (1) PT3083627T (enExample)
RS (1) RS58053B1 (enExample)
SG (1) SG11201604618TA (enExample)
SI (1) SI3083627T1 (enExample)
SV (1) SV2016005226A (enExample)
TN (1) TN2016000253A1 (enExample)
TW (1) TWI674263B (enExample)
UA (1) UA117046C2 (enExample)
UY (1) UY35903A (enExample)
WO (1) WO2015095477A1 (enExample)
ZA (1) ZA201604415B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016269626B2 (en) 2015-05-29 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents
PL3331885T3 (pl) * 2015-08-07 2021-06-14 Glaxosmithkline Intellectual Property Development Limited Związki
US10399966B2 (en) 2016-01-21 2019-09-03 University Of Washington Compounds for treatment of trypanosomes and neurological pathogens and uses thereof
WO2018176134A1 (en) 2017-03-27 2018-10-04 HYDRO-QUéBEC Salts for use in electrolyte compositions or as electrode additives
JOP20190278A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
EA039324B1 (ru) * 2017-11-06 2022-01-13 Новартис Аг 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
TW202028208A (zh) 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-氟-3-(6-(3-甲基吡啶-2-基)-[1,2,4]三唑并[1,5-a]嘧啶-2-基)苯基)-2,4-二甲基㗁唑-5-甲醯胺固體形式

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
FR2652085A1 (fr) 1989-09-20 1991-03-22 Science Organisation Nouveau procede de synthese de derives d'oxazolopyridines.
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0643588A (ja) * 1992-07-27 1994-02-18 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
JP3735741B2 (ja) * 1995-11-24 2006-01-18 株式会社大塚製薬工場 縮環ピリミジン誘導体
JP2000516611A (ja) 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体
AU4499697A (en) * 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
WO2001070743A1 (en) 2000-03-20 2001-09-27 Axys Pharmaceuticals, Inc. Non-amidine containing protease inhibitors
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
WO2002036580A2 (en) 2000-10-31 2002-05-10 Lynn Bonham Benzoxazole lpaat- beta inhibitors and uses thereof
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
EP1339668A2 (en) 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7488598B2 (en) 2001-10-26 2009-02-10 Cornell Center For Technology Enterprise And Commercialization Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
US7253154B2 (en) 2001-11-16 2007-08-07 Nippon Chemiphar Co., Ltd. Substituted thiazolopyrimidines as xanthine oxidase inhibitors
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2534292A1 (en) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
CN1930159A (zh) 2004-03-08 2007-03-14 北卡罗来纳大学查珀尔希尔分校 作为抗原生动物药的新的双阳离子咪唑并[1,2-a]吡啶和5,6,7,8-四氢-咪唑并[1,2-a]吡啶化合物
CN101087787A (zh) 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 苯甲酰胺衍生物,它们的制备及作为药剂的应用
CA2589877A1 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
CN101208338B (zh) 2005-07-29 2010-12-29 霍夫曼-拉罗奇有限公司 氮杂苯并咪唑衍生物,它们的制备以及作为抗癌剂的应用
US7776878B2 (en) 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
CA2618370A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
PL2054405T3 (pl) 2006-07-11 2014-03-31 Dae Woong Pharma Nowe pochodne biarylobenzimidazolu i zawierająca je kompozycja farmaceutyczna
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008100376A2 (en) 2007-02-15 2008-08-21 Sirtris Pharmaceuticals, Inc. Truncation variants of sirt1 and methods of use thereof
WO2009005551A2 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP2146969A1 (en) 2007-04-19 2010-01-27 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Raf激酶抑制劑之化合物
EP2197979B1 (en) 2007-10-17 2016-12-07 Cheil Industries Inc. Novel compound for organic photoelectric device and organic photoelectric device including the same
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR101354763B1 (ko) 2008-08-25 2014-01-22 아이알엠 엘엘씨 헷지호그 경로 조절제
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
TWI421252B (zh) * 2009-07-09 2014-01-01 Irm Llc 用於治療寄生蟲疾病之化合物及組合物
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
ES2527835T3 (es) * 2009-09-29 2015-01-30 Board Of Regents, The University Of Texas System Agentes anti malaria que son inhibidores de dihidroorotato deshidrogenasa
EP2528893B1 (en) * 2010-01-29 2018-10-10 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
WO2011153377A2 (en) 2010-06-03 2011-12-08 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (cns) injury
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物
US9206164B2 (en) 2011-03-25 2015-12-08 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
EP3628320B1 (en) 2011-11-11 2022-03-16 Gilead Apollo, LLC Acc inhibitors and uses thereof
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
HK1203948A1 (en) * 2012-03-07 2015-11-06 Merck Patent Gmbh Triazolopyrazine derivatives
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
AR091586A1 (es) 2012-06-28 2015-02-11 Fujifilm Corp Derivado de amida o su sal como inhibidor de la produccion de colageno
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014028968A1 (en) 2012-08-21 2014-02-27 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Also Published As

Publication number Publication date
US9700559B2 (en) 2017-07-11
MY175865A (en) 2020-07-14
GT201600131A (es) 2018-12-18
US11123348B2 (en) 2021-09-21
US20210369716A1 (en) 2021-12-02
US20170333437A1 (en) 2017-11-23
AR098844A1 (es) 2016-06-15
AU2014364565B2 (en) 2017-06-15
AU2014364565A1 (en) 2016-07-14
PT3083627T (pt) 2018-11-30
PH12016501198A1 (en) 2016-08-15
UY35903A (es) 2015-07-31
EP3083627A1 (en) 2016-10-26
TN2016000253A1 (en) 2017-10-06
US9303034B2 (en) 2016-04-05
CY1121060T1 (el) 2019-12-11
CN106029666A (zh) 2016-10-12
MA39186A1 (fr) 2017-11-30
LT3083627T (lt) 2018-12-27
PE20160865A1 (es) 2016-09-03
MX2016008079A (es) 2016-09-16
US20200179391A1 (en) 2020-06-11
EA201691271A1 (ru) 2016-12-30
EP3083627B1 (en) 2018-09-05
IL246034B (en) 2020-02-27
ZA201604415B (en) 2017-09-27
SG11201604618TA (en) 2016-07-28
MX368072B (es) 2019-09-18
TW201609734A (zh) 2016-03-16
US20190000852A1 (en) 2019-01-03
JP6392352B2 (ja) 2018-09-19
US10085989B2 (en) 2018-10-02
CA2932870A1 (en) 2015-06-25
RS58053B1 (sr) 2019-02-28
CU20160090A7 (es) 2017-05-10
CU24379B1 (es) 2019-02-04
US20150175613A1 (en) 2015-06-25
US20160303129A1 (en) 2016-10-20
HUE040254T2 (hu) 2019-02-28
JP2017501177A (ja) 2017-01-12
HRP20182021T1 (hr) 2019-01-25
CN106029666B (zh) 2018-05-18
PL3083627T3 (pl) 2019-02-28
BR112016014004A2 (enExample) 2017-08-08
CL2016001421A1 (es) 2016-12-30
CR20160334A (es) 2016-12-06
US10596175B2 (en) 2020-03-24
WO2015095477A1 (en) 2015-06-25
KR102354082B1 (ko) 2022-01-24
NZ721650A (en) 2018-12-21
CA2932870C (en) 2021-11-09
IL246034A0 (en) 2016-08-02
KR20160093077A (ko) 2016-08-05
BR112016014004B1 (pt) 2022-11-01
AP2016009329A0 (en) 2016-07-31
SI3083627T1 (sl) 2019-01-31
SV2016005226A (es) 2019-04-23
ECSP16067921A (es) 2017-10-31
UA117046C2 (uk) 2018-06-11
TWI674263B (zh) 2019-10-11
EA030823B1 (ru) 2018-10-31
ES2701087T3 (es) 2019-02-20

Similar Documents

Publication Publication Date Title
CY2022003I2 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
DK3523301T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
HUE053067T2 (hu) Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
DK3077397T3 (da) 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
DK3324977T3 (da) Benzodiazepinderivater som rsv-inhibitorer
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
DK3419978T3 (da) Pyrazolo[1,5-A]pyrazin-4-yl-derivater som JAK-hæmmere
EA201591420A1 (ru) Гетероарильные соединения и их применение
DK3019496T3 (da) Pyrimidinderivater som kinaseinhibitorer
EA201491456A1 (ru) Соединения-ингибиторы raf
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DK3134413T3 (da) Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
DK3380471T3 (da) Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
EP3508487A4 (en) PYRAZOLO [1,5-A] PYRIMIDINE COMPOUND
DK3578562T3 (da) L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme
EP3551630A4 (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы